This article from a few weeks ago focused on the misuse of the “Burning Platform” approach to change management. This article applies the insights to BioTech leaders. 

Building genuine buy-in for change is one of the hardest challenges BioTech leaders face. Clinicians, regulators, partners, and patients all carry a strong status quo bias, not because they are stubborn, but because existing approaches feel familiar, safer, and professionally defensible.

When progress stalls, the temptation is to manufacture urgency. To declare a crisis. To frame delay as a moral failure. To create a burning platform that forces movement.

That shortcut is understandable. It is also dangerous.

When leaders manufacture urgency rather than earn trust, they may get motion but lose credibility. And in BioTech, credibility is everything. Once trust erodes, adoption slows, scrutiny hardens, and even promising treatments struggle to recover.

We have seen this dynamic play out publicly in climate advocacy, where exaggerated urgency, moralized debate, and visible hypocrisy triggered backlash and sidelined sensible solutions. The lesson for BioTech leaders is not about climate. It is about change leadership in the face of uncertainty.

The same patterns that destroyed trust there quietly undermine buy-in for new therapies, platforms, and care models every day.

What follows are five leadership lessons for moving from manufactured urgency to durable trust, and for earning real buy-in that improves patient outcomes rather than forcing compliance that quickly unravels.

Lesson #1: Urgency Without Proportion Destroys Credibility

One of the fastest ways to lose trust is to overstate certainty.

In climate messaging, probabilistic forecasts were often framed as inevitable outcomes. Nuance disappeared. When reality failed to align perfectly with predictions, confidence cracked.

In BioTech, this happens when early or incomplete data are presented as definitive, when risks are minimized, or when uncertainty is treated as a communications liability instead of a scientific reality.

It shows up when leaders say:

• “This is the only viable option”
  
• “We cannot afford debate”
  
• “Anyone who questions this doesn’t care about patients”

Clinicians, regulators, and patients do not expect omniscience. They do expect intellectual honesty. Confidence earns followership. False certainty breeds quiet resistance.

Lesson #2: Permanent Crisis Mode Creates Fatigue, Not Adoption

Humans cannot live indefinitely in emergency mode.

Climate advocates rang the alarm bell year after year, always louder, always more urgent. The result was not sustained engagement. It was numbness.

BioTech leaders fall into the same trap when every message implies catastrophe if adoption is not immediate, when every delay is framed as patients dying because someone asked a tricky question.

Inside organizations and clinical communities, this sounds like:

• Every trial is “make or break”
  
• Every quarter is “critical”
  
• Every regulatory question is treated as an existential threat

Eventually, people stop listening, not because they don’t care, but because their nervous systems are exhausted. Urgency is a spark, not a fuel source. If everything is on fire, nothing is.

Lesson #3: Moralizing Science Turns Partners into Opponents

Perhaps the most damaging mistake in climate advocacy was collapsing disagreement into moral failure.

Questioning tactics became questioning science. Questioning trade-offs became questioning values. Debate became heresy.

In BioTech, this shows up when:

• Skeptics are labeled “anti-science”
  
• Legitimate concerns are treated as disloyalty
  
• Values language is used to shut down dialogue rather than deepen it

Here is the paradox. The more righteous the tone, the weaker the case.

Scientists, clinicians, and regulators do not resist because they lack morals. They resist when they feel dismissed, coerced, or disrespected. Medicine advances through scrutiny, challenge, and dissent. Silencing those forces undermines credibility rather than protecting it.

Lesson #4: Hypocrisy Is Fatal to Change Leadership

Nothing kills change faster than unequal sacrifice.

In climate advocacy, credibility collapsed when elites demanded restraint while exempting themselves. In BioTech, hypocrisy is usually quieter, but its effects are just as corrosive.

It shows up when leaders:

• Push aggressive timelines while insulating themselves from clinical, regulatory, or reputational risk
  
• Reward speed to market, while others bear the consequences if real-world performance falls short
  
• Preach patient-centricity while incentives reward speed, volume, or market capture over durable outcomes
  
• Talk about transparency while selectively disclosing inconvenient data or unresolved risks

These signals are not missed. Clinicians, regulators, and patients are highly attuned to whether risk is being shared or quietly transferred. People will accept risk when they believe it is shared. They resist when they sense it is being transferred.

Lesson #5: Fear Can Force Compliance, But Not Commitment

Fear can make people move. It cannot make them believe.

In BioTech, a treatment adopted under pressure is inherently fragile. The first safety signal, competing study, reimbursement challenge, or regulatory question can unravel months or even years of progress.

When adoption is driven by urgency alone, confidence remains shallow. Clinicians comply, but they do not commit. Regulators approve, but they scrutinize relentlessly. Patients enroll, but hesitation lingers just beneath the surface.

Climate advocacy often substituted fear for agency. People were told what to fear but were not meaningfully invited to solve the problem.

BioTech leaders repeat this mistake when they:

• Announce new therapies or platforms without co-creating pathways with clinicians and care teams
  
• Declare urgency without a transparent, credible plan for evidence generation, safety monitoring, and real-world use
  
• Demand buy-in from partners and regulators instead of earning confidence through openness and shared learning

Compliance can look like progress on a dashboard. Until pressure eases, new data emerge, or incentives shift, and everything snaps back.

Lasting adoption is built on confidence, not coercion. And confidence grows when people feel respected, informed, and genuinely invited to participate in advancing better patient outcomes.

What Real Buy-In Requires

People lean forward and offer their discretionary effort when three conditions are met:

1. They are clear about what must change and why
   
2. They believe the game plan has a real chance of working
   
3. They conclude they are better off buying in

Without clarity, you create confusion. Without confidence, you create cynicism. People resist when they believe change leaves them worse off.

Climate hysteria failed on all three counts. The backlash was not inevitable. It was earned.

The Deeper Leadership Lesson

Successful change management is not about the strength of the science, the elegance of the platform, or the urgency of the message.

It is about the strength of trust in you. People do not want to be scared into change. They want to be respected and included in the contribution.

For BioTech leaders committed to better patient outcomes, that distinction is not academic. It is decisive.